Sign inJoin waitlistJoin the waitlist

Paul Oberstein

Assistant Director, Pancreatic Cancer Center at Perlmutter Cancer Center · NYU Grossman School of Medicine

Credentials: · · · ·

History

Gastrointestinal Medical Oncology Program Division · NYU Grossman School of Medicine
Present
NYU Grossman School of Medicine
Present
NYU Grossman Long Island School of Medicine · NYU Grossman School of Medicine
Present

Medical Oncology
2009–2011
Internal Medicine
Temple University Hospital
2006–2009
Ohio State Univ Coll of Med
2002–2006

Research

Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma
Cancer Cell · 2014 · 1,739 citations
Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma
Journal of Clinical Oncology · 2020 · 422 citations
HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal…
Journal of Clinical Oncology · 2018 · 407 citations

Diane Simeone
6 papers
Gulam Manji
6 papers
John Chabot
6 papers
Lauren Khanna
6 papers
Alina Iuga
5 papers
Helen Remotti
5 papers
Nathan Bahary
5 papers
Tamas Gonda
5 papers
Zev Wainberg
5 papers
Andrew Hendifar
4 papers
Beth Schrope
4 papers
Philip Philip
4 papers

Clinical trials

A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
Principal investigator · Active not recruiting · Phase 1
NYU Langone Health
2023–2026
Feasibility of a Health Care Provider Guided Exercise Intervention Prior to Surgical Resection of Pancreatic Cancer
Principal investigator · Completed
NYU Langone Health
2022–2024
A Phase II a Study of Lenvatinib, a Multi-targeted Tyrosine Kinase Inhibitor, Combined With Pembrolizumab (PD-1 Inhibitor) for the Treatment of Metastatic Gastroesophageal Cancer Patients Who Have Progressed on First or Subsequent Line Therapies
Principal investigator · Completed · Phase 2
NYU Langone Health
2017–2024
A Study of Gemzar, Taxotere, and Xeloda for Adjuvant Pancreatic Cancer
Principal investigator · Completed · Phase 2
Columbia University
2006–2014